Focus Partners Wealth
LAB icon

Focus Partners Wealth’s Standard BioTools LAB Stock Holding History

Focus Partners Wealth’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.3K Buy
46,565
+22,340
+92% +$21.1K ﹤0.01% 2696
2026
Q1 		$22.3K Buy
24,225
+9,582
+65% +$11.6K ﹤0.01% 2608
2025
Q4 		$18.7K Sell
14,643
-392
-3% -$527 ﹤0.01% 2629
2025
Q3 		$19.5K Sell
15,035
-92
-0.6% -$121 ﹤0.01% 2187
2025
Q2 		$18.2K Sell
15,127
-155
-1% -$172 ﹤0.01% 2007
2025
Q1 		$16.5K Buy
15,282
+1,227
+9% +$1.72K ﹤0.01% 1876
2024
Q4 		$24.6K Buy
14,055
+1,053
+8% +$1.96K ﹤0.01% 1845
2024
Q3 		$25.1K Buy
+13,002
New +$25.5K ﹤0.01% 1553

Other funds holding LAB

Casdin Capital
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
MAK Capital One
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $504M AUM 26.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Focus Partners Wealth's LAB Position: Q2 2026 in Review

Focus Partners Wealth increased its Standard BioTools (LAB) stake by 92% in Q2 2026, buying an estimated $21.1K and bringing the position to 46,565 shares worth $38.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2696.

Focus Partners Wealth first reported a position in LAB in Q3 2024 and has held it in 8 quarters since. 143 funds tracked by Wall St. Rank hold LAB as of Q2 2026.

  • Focus Partners Wealth held 46,565 shares of Standard BioTools worth $38.3K as of Q2 2026.
  • Focus Partners Wealth bought 22,340 Standard BioTools shares in Q2 2026, an estimated $21.1K.
  • Standard BioTools made up ﹤0.01% of Focus Partners Wealth's portfolio in Q2 2026, its #2696 holding.
  • Focus Partners Wealth first reported a position in Standard BioTools in Q3 2024 and has held it in 8 quarters since.
  • 143 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2026.

Based on Focus Partners Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.